Medical/Pharmaceuticals

Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor

-  The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once-daily or potentially once-weekly oral dosing. -  ASC50 had strong target engagement after a single oral dose, in...

2025-12-15 17:00 9749

DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT

* Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient * The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressu...

2025-12-15 15:02 4655

Manulife and Bupa Sign MoU for Strategic Collaboration in Hong Kong to Create a More Robust, Integrated Healthcare Network Offering Customers Greater Access and Choice

HONG KONG, Dec. 15, 2025 /PRNewswire/ -- Manulife (International) Limited ("Manulife") and Bupa International Limited ("Bupa") are pleased to announce today the signing of a Memorandum of Understanding ("MoU"), intended to establish a strategic collaboration inHong Kong that will provide customer...

2025-12-15 13:45 3663

Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder

SHANGHAI, Dec. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the launch of its 2030 Strategy, out...

2025-12-15 12:40 4397

AbbVie Ranked #15 in the Inaugural Fortune 100 Best Companies to Work For Southeast Asia 2025 List

SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- AbbVie ASEAN has been ranked #15 in the inauguralFortune Best Companies to Work For Southeast Asia 2025 list, in partnership with Great Place To Work®, highlighting workplaces acrossSingapore, Malaysia, Thailand and the Philippines.

2025-12-15 09:00 7874

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

Announcement Highlights: * Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. * The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CY...

2025-12-15 08:25 2700

ALL CONEC Signs MOU with MINIMAX to Accelerate Global Digital Dental Expansion

SEOUL, South Korea, Dec. 13, 2025 /PRNewswire/ -- ALL CONEC has signed a memorandum of understanding (MOU) with Australian digital dental company MINIMAX to jointly promote digital implant production, marking a strategic move to expand into global markets. The collaboration will validate implant...

2025-12-13 08:00 4278

TraceLink Supports UNICEF's Traceability and Verification System (TRVST) to Advance Safe, Authentic Medicine Access Globally

TraceLink announced its support for UNICEF's Traceability and Verification System (TRVST), a global initiative improving the safety, authenticity, and traceability of medicines in regions vulnerable to falsified or substandard products. By supporting TRVST, TraceLink reinforces its position as th...

2025-12-12 00:21 3652

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease  leveraging Everest's existing commercial organization - Exclusive Greater China license to develop and commercialize Lerodalcibep, a novel, small protein-bindin...

2025-12-11 23:57 4730

ProPharma Expands Operations with New Office in Hyderabad

Modern workspace supports continued growth and innovation RALEIGH, N.C., Dec. 11, 2025 /PRNewswire/ -- ProPharma , the leading global provider of regulatory, clinical, and c...

2025-12-11 21:10 2306

MATELASER W1 REGEN: The Lightest 24g and Highest 5,100 mW/cm² Wearable Red Light Therapy Device Debuts on Kickstarter

MIAMI, Dec. 11, 2025 /PRNewswire/ -- MATELASER, INC., a pioneer in mobile laser therapy, today announced the official launch of its global crowdfunding campaign for the W1 REGEN, a breakthrough device that brings clinic-grade laser therapy into an ultra-miniature 24g wearable form. Priced at just...

2025-12-11 20:30 2664

The 2nd International Cerebro-cardiovascular Medical Innovation Summit (ICMIS 2025) Opens in Hong Kong: AI Technology and Digital Health Usher in a New Chapter of Translational Medicine.

HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Cerebro-cardiovascular conditions have continued to pose a public health burden. The convergence of population ageing and lifestyle risk factors has made "earlier detection, earlier intervention, and accessible and affordable prevention and management" a c...

2025-12-11 19:19 2909

NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO

* Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistance * The study a...

2025-12-11 14:12 3360

Rhinocare Korea Accelerates Global Expansion with Singapore Joint Venture

K-Healthtech Firm Targets Rapid Global Scale-Up with Drug-Free Nasal-Care Innovation SINGAPORE and SEOUL, South Korea, Dec. 11, 2025 /PRNewswire/ -- Rhinocare Korea, a medtech innovator specializing in drug-free respiratory care, announced plans to establish a joint venture (JV) inSingapore as p...

2025-12-11 12:46 4029

Hakka Medicine: From Millennia of Heritage to Modern Industrialization - A Health Path Connecting the World

HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Hakka medicine is the result of deep integration between traditional Central Plains Chinese medicine and the natural environment of southernChina, carrying profound historical heritage and unique clinical value.The  Seventh World Hakka Entrepreneurs Conven...

2025-12-11 08:00 2324

Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration

MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinica...

2025-12-11 03:30 2907

DNV LAUNCHES ACCREDITATION FOR AMBULATORY SURGERY CENTERS

New offering builds on DNV's value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes HOUSTON, Dec. 10, 2025 /PRNewswire/ -- DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory...

2025-12-10 22:16 5987

Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006

HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals") and Formation Bio today announced Formation Bio's acquisition of worldwide rights, excludingGreater China, to LNK01...

2025-12-10 22:05 8114

Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics

Two leading entities in cancer research pledge scientific collaboration to advance precision oncology. HAMBURG, Germany and ROCHESTER, N.Y., Dec. 10, 2025 /PRNewswire/ -- Indivumed is excited to announce its partnership with the world-renowned Wilmot Cancer Institute at theUniversity of Rocheste...

2025-12-10 21:00 3708

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial. HONG KONG, Dec. 10, 2025 ...

2025-12-10 17:15 4520
1 ... 52535455565758 ... 382